source
- Viatris to acquire Pacira BioSciences for $1.65 billion, adding two non-opioid pain drugsViatris announced Thursday it will purchase Pacira BioSciences for $1.65 billion in cash, paying $36.50 per share, a 45% premium to the prior close. The acquisition gives Viatris control of Pacira…
- Iambic Therapeutics targets $135M IPO to fund clinical trials of HER2 and KIF18A cancer drugsIambic Therapeutics, a San Diego AI‑driven biotech, filed to raise $135 million in net proceeds through an initial public offering. The company plans to sell 9.4 million shares at $15 to $17 each,…